Jupiter Wellness’ Merger Partner Next Frontier Pharmaceuticals, Inc. Announces Plans for Oral Dronabinol Solution for the Treatment of Alzheimer’s Disease Agitation

Next Frontier Pharmaceuticals is pursuing FDA 505(b)(2) fast-track approval with its previously FDA approved oral dronabinol (THC) solution Next Frontier Pharmaceuticals has completed a pre-IND meeting with the FDA, and intends to commence Phase II Clinical Trials in the 2H 2022; industry research and studies support targeted efficacy endpoints Alzheimer’s Disease Agitation (Agit-AD) is estimated […]